Video Recordings of Multidisciplinary Clinics for People With ALS and Their Caregivers

This study is looking at whether video recordings of multidisciplinary clinic (MDC) visits can improve the quality of life for people with Amyotrophic Lateral Sclerosis (ALS) and their caregivers. People with ALS often receive a lot of information during these long clinic visits, which can be hard to remember. This study will provide participants with video recordings of their MDC visits, accessible through a secure online platform called HealthPAL. Participants will also receive instructions on how to view their after-visit summaries and doctor's notes in their patient portal. The study aims to enroll 800 participants and will measure changes in quality of life using surveys over 12 months. To join, you must be at least 18 years old, have an ALS diagnosis, plan to attend MDC visits for 12 months, speak English or Spanish, and have a caregiver who also participates.

Study design
This is an interventional study planning to enroll 800 participants. It will compare the impact of video recordings and notes instruction on quality of life.
What's involved
Participants will have their multidisciplinary clinic visits video recorded for 12 months and receive instructions on accessing patient portal notes. Quality of life surveys will be completed at enrollment, 1 month, 6 months, and 12 months.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 12 months after enrollment, with surveys administered at 1 month, 6 months, and 12 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07454733

Do Video Recordings of Multidisciplinary Clinics Improve Quality of Life for People With ALS and Their Caregivers?

Not Yet Recruiting
NAAges 18+Interventional
Trustees of Dartmouth College
~800 participants
Updated 2026-03-06 on ClinicalTrials.gov
What's tested:Video recordingNotes Instruction

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
For Caregiver Participants: the total score on the PROMIS-10 self report survey
Measured over Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.
+1 more outcome measured
Amyotrophic Lateral Sclerosis (ALS)

NCT07454733

Where you'd take part

This study runs at 7 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Dartmouth-Hitchcock Health

    Lebanon, New Hampshirestudy coordinator listed

  • Massachusetts General Hospital

    Boston, Massachusettsstudy coordinator listed

  • Mayo Clinic Jacksonville

    Jacksonville, Floridastudy coordinator listed

  • Mayo Clinic Scottsdale

    Scottsdale, Arizonastudy coordinator listed

  • Penn State Health Milton S. Hersey Medical Center

    Hershey, Pennsylvaniastudy coordinator listed

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvaniastudy coordinator listed

  • University of Wisconsin Health

    Madison, Wisconsinstudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

  • Paul J Barr, PhD · PRINCIPAL_INVESTIGATOR · Dartmouth College
  • Suma Babu, MD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of ALS by either El- Escorial or Gold Coast Criteria
≥18 years of age
Plan to attend MDC visits for 12 months
Speak English or Spanish
Presence of a caregiver (defined as someone who assists with care) who is also participating in the VITALS trial
Projected life expectancy of at least 12 months as determined by the site investigator.
Agree to their identified role as a caregiver of a patient with ALS participating in the VITALS trial;
Speak English or Spanish;
≥18 years of age.

Exclusion

Unable or unwilling to provide informed consent or follow study procedures
Significant cognitive impairment, clinical dementia, or unstable psychiatric illness (including, but not limited to, psychosis, active suicidal ideation, suicide attempt, or untreated major depression) as determined by the site investigator
Current pregnancy based on participant self-report;
Unable to access the internet;
Do not have access to a personal or shared email and are not interested in creating a personal or shared email;
Do not wish to create a patient portal account, if they do not already have one;
Uncorrected hearing or visual impairment that would impair the ability to view video recordings;
Incarcerated.
Unable or unwilling to provide consent or follow study procedures;
Unable to access the internet;
Do not have access to a personal or shared email and are not interested in creating a personal or shared email;
Uncorrected hearing or visual impairment;
Professional caregiver for the patient;
Incarcerated.
  • For Caregiver Participants: the total score on the PROMIS-10 self report surveyAdministered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

    The Patient-Reported Outcomes Measurement Information System-10 (PROMIS-10) is a self-report measure of quality of life. The PROMIS-10 will be administered to caregivers via a secure online survey. We will analyze the total score on the PROMIS-10 as the primary outcome for caregiver participants.

  • For Patient Participants: The total score on the ALSAQ-40 self report survey.Administered at enrollment (baseline) and 1 month, 6 months, and 12 months after enrollment.

    The Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) is a self-report measure of quality of life for people with ALS. The ALSAQ-40 will be administered via a secure online survey.